Physician profile
Neel N Shah
NPI 1861752529
$3,203.96
in general payments reported to CMS, 2019-2025
27 companies · $1,798 in 2025
The $1,798 reported for 2025 was more than what 77% of Vascular Neurology providers received nationally (typical 2025 total: $360).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $377 · 2020: $13.58 · 2022: $51.56 · 2024: $963 · 2025: $1,798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,761.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $349.66 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $348.59 | 2019-2025 | |
| Ucb, INC. | $291.29 | 2024-2025 | Briviact, Nayzilam, Fintepla |
| Sk Life Science, INC. | $259.01 | 2024-2025 | |
| Abbvie INC. | $233.43 | 2024-2025 | |
| Biogen, INC. | $213.74 | 2024-2025 | Vumerity, Leqembi |
| Teva Pharmaceuticals USA, INC. | $196.62 | 2024-2025 | Austedo Xr, Austedo Xr |
| Amgen INC. | $192.56 | 2019-2025 | Uplizna |
| Inari Medical, INC. | $170.35 | 2019 | |
| Portola Pharmaceuticals, LLC | $116.99 | 2019 | |
| Amneal Pharmaceuticals LLC | $108.78 | 2024-2025 | Crexont, Rytary |
| Lundbeck LLC | $98.60 | 2025 | Rexulti, Vyepti |
| Alnylam Pharmaceuticals INC. | $84.21 | 2024-2025 | Onpattro, Amvuttra |
| Genentech USA, INC. | $71.02 | 2020-2025 | Ocrevus Zunovo |
| Otsuka America Pharmaceutical, INC. | $65.86 | 2024 | Rexulti |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $63.09 | 2025 | Vyvgart Hytrulo |
| Axsome Therapeutics, INC. | $53.54 | 2025 | Symbravo, Sunosi |
| Astrazeneca Pharmaceuticals Lp | $51.56 | 2022 | |
| Neurocrine Biosciences, INC. | $43.52 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $41.07 | 2019-2024 | Ultomiris |
| Harmony Biosciences LLC | $35.84 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $22.50 | 2024 | Ponvory |
| Mdd US Operations, LLC | $19.58 | 2025 | |
| Lilly USA, LLC | $19.26 | 2025 | Kisunla |
| Grifols USA, LLC | $18.22 | 2024 | Gamunex-C |
| Bausch Health US, LLC | $17.85 | 2019 | |
| Aucta Pharmaceuticals, INC. | $17.22 | 2025 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neel Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.